Home Category Region Publishers About Us Contact Us
Japanese Korean Chinese
Home > Market Research Report > Pharmaceutical > Pharmaceutical Companies > Partneringreview 2006 - Company deal index (volume 1)
Category
Pharmaceutical (4989)
Bone Disease Treatment (46)
Cancer (883)
Diabetes (159)
Drug Delivery System (184)
Drug Discovery (1403)
Generic Drugs (128)
Infectious Disease (406)
Mental Disease (98)
Neurodegenerative Disease (180)
Obesity Treatment (49)
OTC Drug (149)
Pharmaceutical Companies (562)
Prescription Drugs (120)
Regulation (122)
Vaccines (178)
Veterinary Medicine (28)
Market Research Report

Partneringreview 2006 - Company deal index (volume 1)

Published by Pharmalicensing Ltd.
Published February, 2006 Product code 36675
Content info 1852 pages
Price
US $ 2495 PDF by E-mail (Single User License)


Partneringreview 2006 - Company deal index (volume 1) published by Pharmalicensing Ltd. in February, 2006. This report consists of 1852 pages and the price starts from US $ 2495.

Introduction

Abstract

Partneringreview 2006 - Volume 1: Company deal index provides an in depth view into the deals by company, with a full index of all the deals, including mergers, acquisitions and financings announced in 2005. A clear and easy way to see the activities of any company.

Every deal by every company listed alphabetically.

Every deal is fully categorized, includes a detailed description, and includes financials such as headline value, upfront and milestone payments, where disclosed.

Each deal is annotated with a deal number, such as #43. This number links to the full deal in the deal listing at the rear of each report. When using the PDF format in Acrobat Reader, simply click on the number to move around the report.

The report includes the deals announced by hundreds of companies including the top 50 biopharma: Pfizer, GlaxoSmithKline, Sanofi-Aventis, Johnson & Johnson, Merck, Novartis, AstraZeneca, Roche, Bristol-Myers Squibb, Wyeth, Abbott Labs, Eli Lilly, Amgen, Takeda, Boehringer Ingelheim, Schering-Plough, Schering AG, Bayer, Eisai, Teva, Merck KGaA, Yamanouchi, Otsuka, Novo Nordisk, Baxter, Fujisawa, Sankyo, Forest Labs, Akzo Nobel, Altana, Serono, Solvay, UCB, Genzyme, Allergan, Mitsubishi Pharma, Shionogi, Watson, IVAX, Alcon, H Lundbeck, Biogen Idec, Mylan Labs, Shire, Ono, Tanabe Seiyaku, Daiichi, Barr, Gilead Sciences, Purdue Pharma.

All the year' s deals at a glance.

Want to know what your competitors are doing? Want to benchmark your deals against others in your therapeutic area or see how the finances of different deal types compare? Partneringreview 2006 brings all the 2005' s deals into focus in one place.

Partneringreview is a comprehensive summary of the year' s deal announcements in a clear and accessible printable format. Every deal entry includes financial information where disclosed, such as headline values and upfront and milestone payments. A new addition of an overview of financings from investors is also included in this latest edition.

Partneringreview 2006 is the full report of all the deals data collected in 2005, providing a broad perspective of deal announcements, and incorporates all six volumes.

Table of Contents

INTRODUCTION

  • About Partneringreview
  • Full contents of Partneringreview 2006
  • Review of deal making in 2005
  • Deals announced by company

VOLUME 1: COMPANY DEAL INDEX

  • Chapter 1: Deals by company
  • Chapter 2: M&A by company
  • Chapter 3: List of deals

GLOSSARY

List of tables, charts

Figures

  • Figure i.1 Partnering announcements by company 2004 vs 2005
  • Figure i.2 Top 25 pharma deal activity 2004 vs 2005
Back to Top